Methotrexate treatment rheumatoid arthritis

Long term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely the result of laboratory abnormalities. Comparison of two schedules for administering oral low-dose methotrexate in patients with rheumatoid arthritis in remission: a twenty-four week, single blind, randomized study. Every-other week methotrexate in patients with rheumatoid arthritis: A double-blind, placebo-controlled prospective study. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Longterm treatment of destructive rheumatoid arthritis with methotrexate. Paucity of radiographic progression in rheumatoid arthritis treated with methotrexate as the first disease modifying antirheumatic drug. Radiologic progression in early rheumatoid arthritis treated with methotrexate. Safety, efficacy, and mortality in a long-term cohort of patients with rheumatoid arthritis taking methotrexate: Follow-up after a mean of 13.3 years.